IMC-F106C-101 (PRAME)

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Code NKI: M23IMC
  • Code firma: IMC-F106C-101 (PRAME)
  • Code clinicaltrials.gov: NCT04262466

Principal Investigator

Dr. N. Steeghs

Drugs

IMC-F106C (MTAC TCR CD3 T-cell and PRAME tumor antigen presented by HLA-A*02:01) monotherapy or icm with chemo/immuno/targteted therapy.

  • Merkelcell cohort – closed
  • Any solid tumor cohort – closed
  • Bladder carcinoma cohort – closed
  • NSCLC cohort – open
  • Ovarian carcinoma cohort- open
  • Endometrial carcinoma cohort – open
  • Melanoma cohort – closed

Summary

IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.

Read more on clinicaltrials.gov